Poster Submissions are welcome!

We encourage scholars, researchers and industry stake-holders to submit poster abstracts for Metabesity 2021. Suggested topic areas are listed on this page.

Download Abstract Submission Instructions

Download Abstract Template

Submit an Abstract

​
Information for Poster Presenters

Format
Electronic poster information (including file type, size, title banner, content, and organization requirements) will be provided once submitting authors have been notified of abstract acceptance.

Presentation
At least one author of accepted poster abstracts must be present during an assigned virtual session to allow for dialogue with participants.

Publication
All abstracts will be published on the conference website at www.metabesity2021.org.

Registration
If your poster is selected for presentation, you are required to register for the conference. Registration is free.

Register Online Now

Register Here Free

Abstract Topic Areas

General Approaches and Tools for Metabesity

• Metabesity pathways and signaling (choke points and pleotropic agents that leverage 2 or more major clinical outcomes)
• Animal model development
• Biomarkers and imaging
• Efficacy endpoints—functional, quality life survival, person-reported
• Microbiome (mechanisms, characterization, interventions)
• General issues related to repurposing approved therapies
• Acquiring and managing big data
• Biostatistical methods
• Cost-effectiveness approaches relevant to payors and policy makers
• Regulatory approaches
• Apps and other engagement and tracking tools
• Education 
• Econometrics
• Bioethics 
• Public policy and public health approaches

 Aging and Sarcopenia 

• Metabolic pathways and signaling
• Genomic and other means of high risk identification
• Validation of targets
• Animal model studies
• Evaluation of candidate interventions (nutritional, pharmacologic, life style) 
• Methods to interpret translatability of animal results
• Clinical efficacy endpoints validation (functional and person-reported instruments) 
• Proposed clinical design approaches
• New clinical study results
• Epidemiology analysis and studies 
• Comparison of major regulatory positions
• Specific bioethical considerations

Cancer

• Metabolic pathways and signaling
• Validated targets
• Animal study results
• Utility of animal models
• Evaluation of current and novel candidate interventions (nutritional, pharmacologic, life style)
• Genomic and other means of high risk identification
• Clinical studies
• Epidemiology analysis and studies 
• Meta-analyses of clinical studies and lessons learned from chemoprevention trials

Diabetes

• Metabolic pathway and signaling
• Islet biology (embryogenesis and homeostasis of islet mass and function)
• Immunity (pathogenesis and interventions)
• Validation of metabolic, inflammatory, and immunologic targets
• Animal model studies
• Methods to enhance translation of animal results
• Genomic and other means of high risk identification
• Clinical efficacy endpoints validation 
• Proposed clinical design approaches
• Clinical studies
• New analyses of reported clinical trials 
• Lessons learned from T1D and T2D prevention trials
• Comparison of major regulatory positions

Neurodegeneration

• Metabolic pathway and signaling
• Validation of targets
• Animal model studies
• Methods to enhance translation of animal results
• Clinical efficacy endpoints validation 
• Proposed clinical design approaches
• Clinical studies
• Comparison of major regulatory positions​